Dermapharm Holding SE (DMP.DE)
Dermapharm Holding SE operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Grünwald, BV, DE. The stock last traded at $40.05, up 0.75% on the session, giving a market capitalisation of $1.98B. Its beta of 0.86 implies it has historically moved less than the broad market.
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
Dermapharm Holding SE is most often compared with the following Healthcare names: